Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide- based allogeneic hematopoietic stem cell transplantation

Anticancer Research

Volumn 27, Issue 6 C, 2007, Pages 4377-4380

  Goekkurt, Eray ^a   Stoehlmacher, Jan ^a   Stueber, Christian ^b   Wolschke, Christine ^b   Eiermann, Thomas ^b   Iacobelli, Simona ^c   Zander, Axel R ^b   Ehninger, Gerhard ^a   Kröger, Nicolaus ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Glutathione S tranferases; Methylene tetrahydrofolate reductase; Sinusoidal obstruction syndrome

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUTATHIONE TRANSFERASE; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DNA METHYLATION; DNA SYNTHESIS; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADOLESCENT; ADULT; BUSULFAN; CYCLOPHOSPHAMIDE; FEMALE; GLUTATHIONE TRANSFERASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIVER; LIVER DISEASES; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MYELOABLATIVE AGONISTS; PHARMACOGENETICS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 37549040153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Weisberg I, Tran P, Christensen B, Sibani S and Rozen R: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64: 169-172, 1998.
2. Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD and Ulrich CM: Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 22: 1268-1275, 2004.
3. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J et al: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98: 231-234, 2001.
4. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M et al: Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104: 1574-1577, 2004.
5. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK et al: Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 224: 893-899, 1994.
6. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH et al: Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11: 663-669, 2001.
7. Arand M, Muhlbauer R, Hengstler J, Jager E, Fuchs J, Winkler L et al: A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 236: 184-186, 1996.
8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113, 1995.
9. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S et al: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91: 344-354, 2004.
10. Mathews V, Salamun DE, George B, Viswabandya A, Lakshmi K, Bajel A et al: Hepatotoxicity profile of single agent As2O3 in the management of newly diagnosed cases of acute promyelocytic leukemia: Impact on outcome and correlation with genetic polymorphisms. Blood 106: Abstract 893, 2005.
11. Nuckel H, Frey UH, Durig J, Duhrsen U and Siffert W: Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. Leukemia 18: 1816-1823, 2004.
12. Kalayoglu-Besisik S, Caliskan Y, Sargin D, Gurses N and Ozbek U: Methylenetetrahydrofolate reductase C677T polymorphism and toxicity in allogeneic hematopoietic cell transplantation. Transplantation 76: 1775-1777, 2003.
13. Evans WE: Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis. Pharmacogenetics 12: 181-182, 2002.
14. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y et al: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12: 183-190, 2002.
15. Bredschneider M, Klein K, Murdter TE, Marx C, Eichelbaum M, Nussler AK et al: Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther 71: 479-487, 2002.